Insider Selling: OmniAb, Inc. (NASDAQ:OABI) CEO Sells $51,387.52 in Stock

OmniAb, Inc. (NASDAQ:OABI) CEO Matthew W. Foehr sold 13,964 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $3.68, for a total transaction of $51,387.52. Following the sale, the chief executive officer now directly owns 3,798,682 shares of the company’s stock, valued at approximately $13,979,149.76. The trade was a 0.37 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

OmniAb Stock Performance

Shares of NASDAQ OABI opened at $3.65 on Friday. OmniAb, Inc. has a fifty-two week low of $3.10 and a fifty-two week high of $6.55. The company has a market cap of $515.45 million, a PE ratio of -5.89 and a beta of -0.12. The business has a 50-day simple moving average of $3.48 and a two-hundred day simple moving average of $3.90.

Wall Street Analyst Weigh In

Several research firms recently commented on OABI. Benchmark reiterated a “buy” rating and set a $8.00 price objective on shares of OmniAb in a research note on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and set a $11.00 price target on shares of OmniAb in a research report on Thursday, November 14th.

Institutional Trading of OmniAb

A number of institutional investors have recently bought and sold shares of the stock. Hsbc Holdings PLC acquired a new position in OmniAb during the 4th quarter valued at approximately $38,000. Choreo LLC acquired a new position in shares of OmniAb in the 4th quarter valued at $41,000. Rangeley Capital LLC acquired a new position in shares of OmniAb in the 4th quarter valued at $41,000. KLP Kapitalforvaltning AS purchased a new position in OmniAb in the 4th quarter worth $49,000. Finally, CWC Advisors LLC. acquired a new stake in OmniAb during the 3rd quarter worth about $54,000. 72.08% of the stock is currently owned by institutional investors and hedge funds.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.